

Date : ..1435/07/23 -- 2014/05/22 التاريخ

الرقم :14/MS/د.ب./090..... Ref

Subject: Direct Healthcare Professional Communication on the association of Diclofenac, (Rofenac) with cardiovascular risk

Dear Health Care Professional,

We are sending this letter to update you with new information regarding (Rofenac) (active substance: diclofenac), to reflect important safety concerns of cardiovascular risk with the use of diclofenac.

Summary

Available data indicate that the cardiovascular risk with diclofenac is similar to that of the selective COX-2 inhibitors and that consistent with COX-2 inhibitors. Diclofenac is now contraindicated in those with: Ischaemic heart disease, peripheral arterial disease, cerebrovascular disease or established congestive heart failure.

Further Information

An increased risk of heart attack and stroke with some non-selective non-steroidal anti-inflammatory drugs (NSAIDs), such as diclofenac is well recognized, particularly with long term use of high doses and in patients who are already at high risk.

Diclofenac is now contraindicated in patients with established:

- **ischaemic heart disease**
- **peripheral arterial disease**
- **cerebrovascular disease**
- **congestive heart failure (New York Heart Association [NYHA] classification II-IV)**

Healthcare Professionals are advised that patients with these conditions should be switched to an alternative treatment. The new treatment advice applies to systemic formulations (tablets, capsules, suppositories and injection); it does not apply to (gel or cream) formulations of diclofenac.

It is also advised that diclofenac treatment should only be initiated after careful consideration for patients with significant risk factors for cardiovascular events (e.g. hypertension, hyperlipidaemia, diabetes mellitus or smoking).

As the cardiovascular risks of diclofenac may increase with dose and duration of exposure, the shortest duration possible and the lowest effective daily dose should be used. The patient's need for symptomatic relief and response to therapy should be re-evaluated periodically.

Date :..... : التاريخ

الرقم :..... : Ref

The information in this letter has been agreed with the Saudi Food and Drug Authority (SFDA).

Call for reporting of adverse reactions

SPIMACO is committed to global surveillance of all its products, also committed to provide you with current product information. Therefore if you have any question or received any adverse drug reaction, you can contact or send it to the National pharmacovigilance and Drug safety Centre or to the pharmacovigilance department in SPIMACO.

The National Pharmacovigilance & Drug safety Centre (NPC):

Fax: +966-11-205-7662.

Toll free phone: 8002490000.

E-mail: npc.drug@sFDA.gov.sa.

Website: www.sFDA.gov.sa/npc.

Pharmacovigilance department in SPIMACO:


Tel: +966 114774481 Ext 1511, 1512

Fax: +966 11477 3961

Email: Ahmed.Farouk@spimaco.sa

Email: Eslam.Fouad@spimaco.sa

Sincerely Yours,


Ph. Khalid S. Al-Shamari

Product Development &

Regulatory Affairs Director